Guidelines

PP17 Targeting of the histone methyltransferases G9a and GLP in multiple myeloma

February 2019
PP33 miR-15a-5p and miR-21-5p contribute to chemoresistance in acute myeloid leukemia by targeting PDCD4, ARL2 and BTG2

February 2019
PP34 Chromosomal aberrations in chronic myeloid leukemia: response to conventional tyrosine kinase inhibitors and risk of blastic transformation

February 2019
PP35 Efficacy and safety of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients in real-world clinical practice: data from a Belgian registry

February 2019
PP36 In vitro generation of tumor antigen-specific T-cells from healthy donor and patient stem cells

February 2019
PP37 In vitro investigations of the effect of BCR-ABL tyrosine kinase inhibitors on endothelial cell viability

February 2019
PP49 Ravulizumab* (ALXN1210) vs eculizumab in complement inhibitor-naive adult patients with PNH

February 2019
PP50 Non-invasive fetal genotyping of RHCE C/c and E alleles in allo-immunized pregnant women: evaluation of a 7-year experience

February 2019
PP56 Infectious complications of a novel tyrosine kinase inhibitor (ibrutinib) and correlation with immunological markers in patients with malignant hemopathies

February 2019
PP61 A randomized, double-blind, placebo-controlled, phase 3 study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura

February 2019

Top